iBio is having a great day in the market today after announcing new discoveries found by iBio’s scientific collaborator, Carol Feghali-Bostwick, Ph.D. Today, we’ll take a look at the new discoveries found, how the market reacted to the news, and what we can expect to see from the stock moving forward.
New Discoveries In Detail
The new discoveries announced today are an extension of Dr. Feghali-Bostwick’s previous discovery that a peptide derived from endostatin (E4) can prevent or ameliorate fibrosis as determined by lung histology and hydroxyproline content in a widely accepted animal model of the disease. The new information demonstrates that E4 can be dosed orally, and also has the ability to prevent or modify the disease in either a single-dose or repeat-dose oral administration regimen. This is big news to the medical community as it is the first demonstration that an orally-dosed peptide is effective in treating fibrosis in an animal. Following the announcement of the data, Terence Ryan, Ph.D. and Chief Scientific Officer at iBio had the following to say…
“Oral dosing of drugs is generally a patient-preferred route versus injections because of ease of administration, particularly for chronic conditions that require relatively long-term use of a drug. However, oral administration of peptides or protein drugs is rarely found to be effective due to presumed action of digestive enzymes… The success of oral E4 is unexpected but gratifying, and we look forward to evaluating further product candidates using this route of administration.”
How The Market Reacted To The News
As mentioned above, iBio is having a great day in the market today after the announcement of this data. Currently (12:15), the stock is trading at $0.72 per share after a gain of 5.31% so far today.
What We Can Expect To See Moving Forward
Moving forward, I’m expecting to see more positive activity out of IBIO. While the company is still in the experimental phase, they have proven quite a few interesting concepts and today’s announcement is an indication that they will continue to do so. Innovation in medicine is always valuable. While we may have to wait to see the true value of this innovation, investors are clearly excited and I believe that we will see a continuation of positive activity out of this stock.
What Do You Think?
Where do you think IBIO is headed and why? Let us know in the comments below!
[Image Courtesy of Benzinga]